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Abstract
AIM
To analyze the outcomes of living-donor liver trans-
plantation (LDLT) using left-lobe (LL) or right-lobe (RL) 
small-for-size (SFS) grafts.
METHODS
Prospectively collected data of adult patients who 
underwent LDLT at our hospital in the period from 
January 2003 to December 2013 were reviewed. The 
patients were divided into the RL-LDLT group and 
the LL-LDLT group. The two groups were compared 
in terms of short- and long-term outcomes, including 
incidence of postoperative complication, graft function, 
graft survival, and patient survival. A SFS graft was 
defined as a graft with a ratio of graft weight (GW) to 
recipient standard liver volume (RSLV) (GW/RSLV) of < 
50%. The Urata formula was used to estimate RSLV.
RESULTS
Totally 218 patients were included for analysis, with 
199 patients in the RL-LDLT group and 19 patients in 
the LL-LDLT group. The two groups were similar in 
terms of age (median, 53 years in the RL-LDLT group 
and 52 years in the LL-LDLT group, P  = 0.997) but had 
significantly different ratios of men to women (165:34 
in the RL-LDLT group and 8:11 in the LL-LDLT group, 
P  < 0.0001). The two groups were also significantly 
different in GW (P  < 0.0001), GW/RSLV (P  < 0.0001), 
and graft cold ischemic time (P  = 0.007). When it 
comes to postoperative complication, the groups were 
comparable (P  = 0.105). Five patients died in hospital, 
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4 (2%) in the RL-LDLT group and 1 (5.3%) in the LL-
LDLT group (P  = 0.918). There were 38 graft losses, 
33 (16.6%) in the RL-LDLT group and 5 (26.3%) in the 
LL-LDLT group (P  = 0.452). The 5-year graft survival 
rate was significantly better in the RL-LDLT group 
(95.2% vs  89.5%, P  = 0.049). The two groups had 
similar 5-year patient survival rates (RL-LDLT: 86.8%, 
LL-LDLT: 89.5%, P  = 0.476).
CONCLUSION
The use of SFS graft in LDLT requires careful tailor-
made surgical planning and meticulous operation. LL-
LDLT can be a good alternative to RL-LDLT with similar 
recipient outcomes but a lower donor risk. Further 
research into different patient conditions is needed in 
order to validate the use of LL graft.
Key words: Small for size liver graft; Right lobe graft; 
Left lobe graft; Living donor liver transplantation
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Liver transplant has become an established 
treatment for liver failure. The use of living-donor liver 
graft is one important strategy to expand the donor 
pool. The use of left lobe graft remains controversial 
due to the potential problem of small-for-size 
syndrome. This study illustrates that the use of left lobe 
graft can produce outcomes similar to right lobe graft. 
However, the study contains selection bias since most 
of the recipients of left lobe grafts had relatively lower 
Model for End-stage Liver Disease scores and were 
women, who are lighter in weight. Therefore, further 
study should focus on the establishment of criteria for 
the use of left lobe graft to allow safe transplant.
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INTRODUCTION
Living-donor liver transplantation (LDLT) was first 
established as an excellent treatment method for 
children with end-stage liver disease[1-3]. The lack 
of cadaveric liver grafts in Asian countries has led 
to the development of LDLT using the left liver lobe 
(LL)[4] and the right liver lobe (RL)[5], which has 
increased the donor pool[6], allowing more patients to 
be transplanted. The LL is only approximately one-
third of the whole liver[7] and thus is generally not 
adequate for a recipient whose body size is similar to 
or bigger than that of the donor. Hence the RL is more 
preferable. Nonetheless, donor right hepatectomy 
carries a mortality risk of 0.5% whereas it is only 
0.1% in donor left hepatectomy[8]. The use of LL 
was once considered near abandonment because 
oftentimes it was insufficient for the metabolic 
demand of recipients, leading to small-for-size (SFS) 
syndrome. SFS syndrome is caused by a SFS graft, 
which is defined as a graft with a ratio of graft weight 
(GW) to recipient standard liver volume (RSLV) (GW/
RSLV) of < 50%[9-11]. SFS syndrome describes the 
constellation of cholestasis, coagulopathy and ascites; 
it can progress to gastrointestinal bleeding and renal 
failure. Portal hypertension and sinusoidal injury 
may lead to graft failure[12,13]. With SFS syndrome, 
patient survival and graft survival after LDLT would be 
poor[9,14-16]. However, some studies of LL-LDLT did show 
promising results[17-21]. Although lowering graft size 
requirement increases recipient risks, it can improve 
the applicability of LL-LDLT and, mostly importantly, 
reduce donor risks[6]. This retrospective study aimed 
to analyze the outcomes of LDLTs using SFS grafts, be 
them LLs or RLs.
MATERIALS AND METHODS
Data of adult patients who underwent LDLT at our 
hospital in the period from January 2003 to December 
2013 were reviewed. Donor and recipient operations 
were performed as described elsewhere[22]. The 
decision of using LL or RL was multifactorial - with 
donor and recipient factors all considered - but 
principally depended on Model for End-stage Liver 
Disease (MELD) score, GW/RSLV, the ratio of GW to 
recipient body weight, and donor liver anatomy. In 
general, if the estimated volume of a LL exceeded 35% 
of the RSLV, LL would be used. However, graft selection 
was still decided on a case-by-case basis, with 
consideration of various factors including anatomical 
variation and recipient condition (MELD score). The 
bottom line was that the estimated volume of the 
future liver remnant of the donor must not be < 35% 
of the donor’s total liver volume. Standard liver volume 
was calculated using the Urata formula [liver volume 
(mL) = body surface area (m2) × 706.2 + 2.4][7]. If 
a RL graft contained the native middle hepatic vein, 
a single venous cuff would be constructed with a 
venoplasty of the middle and right hepatic veins[23] to 
enhance outflow capacity.
LL graft implantation was similar to RL graft im-
plantation. The procedure was done without bypass. 
The common trunk of the left and middle hepatic 
veins was first anastomosed to the recipient inferior 
vena cava. The portal vein was then anastomosed to 
the recipient portal vein. Clamps were removed to 
allow revascularization. Hepatic arteries were always 
reconstructed under the microscope. As to the method 
of biliary reconstruction, hepaticojejunostomy was 
preferred in LL-LDLT whereas duct-to-duct anastomosis 
was preferred in RL-LDLT unless multiple ductal 
openings were encountered.
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Portal flow measurement and flow modulation
A venous cannula was inserted into the inferior 
mesenteric vein to measure the portal pressure, 
especially if the GW/RSLV was ≤ 35%. The portal 
flow was to be maintained at 100-250 mL/min/100 g 
to prevent SFS syndrome. The use of splenic artery 
ligation and the use of ligation of spontaneous splenic 
renal shunt were determined intraoperatively.
Immunosuppression and prophylaxis regimens
Starting from January 2001, 20 mg of basiliximab was 
given intravenously within 6 h of graft reperfusion and 
on postoperative day 4. Steroid injection was given 
intraoperatively with 1 g of hydrocortisone and on 
postoperative day 1 with 500 mg of hydrocortisone. 
Immunosuppression was maintained with oral 
tacrolimus given within 12 h of transplant at a dosage 
of 0.15 mg/kg body weight/D, and the dose was 
titrated to achieve a trough level of 5-10 ng/mL. 
Mycophenolate mofetil at a dosage of 1-1.5 g/d was 
started within 48 h of transplant and was tapered 
off within 3 mo. Maintenance steroid was not given 
routinely. All recipients also orally took 200 mg of 
fluconazole and 480 mg of cotrimoxazole daily and 400 
mg of acyclovir thrice a day for 3 mo for prophylaxis. 
For patients with renal dysfunction (a creatinine level 
before administration of tacrolimus twice the normal 
level), the tacrolimus trough level was kept at 3-5 
ng/mL, and prednisolone at 20 mg/d was added. 
Pentamidine (300 mg) inhalation was given monthly 
for 3 mo to patients with renal impairment or glucose-
6-phosphate dehydrogenase deficiency because the 
use of acyclovir or cotrimoxazole was prohibited[24]. 
For hepatitis B virus carriers and recipients of grafts 
donated by donors who had hepatitis core antibodies, 
nucleoside analogue monoprophylaxis (entecavir) was 
administered.
Statistical analysis
Patient data used in the study were prospectively 
collected. The patients were divided into the RL-LDLT 
group and the LL-LDLT group. For further analysis, 
they were divided into three groups according to GW/
RSLV: ≤ 35%, > 35%-40%, and > 40%-< 50%. The 
RL-LDLT and LL-LDLT groups were compared in terms 
of short- and long-term outcomes, including incidence 
of postoperative complication, graft function, graft 
survival, and patient survival. Recipient conditions 
were compared on postoperative day 7 and then 
yearly. Continuous variables were expressed as 
medians and interquartile ranges and compared by 
the Kruskal-Wallis test. Categorical variables were 
compared by Spearman’s test. Survival rates were 
plotted as Kaplan-Meier curves and compared by log-
rank analysis. Statistical significance was defined as P 
< 0.05. All statistical calculations were performed with 
SPSS, version 20.0 (SPSS, Chicago, IL, United States), 
by the statistician at the Department of Surgery, The 
University of Hong Kong.
RESULTS
From January 2003 to December 2013, 218 adults 
underwent LDLT with a GW/RSLV < 50%. Nineteen 
of them had LL-LDLT and 199 had RL-LDLT. The two 
groups of patients were similar in terms of age (median, 
53 years in the RL-LDLT group and 52 years in the LL-
LDLT group, P = 0.997) but had significantly different 
ratios of men to women (165:34 in the RL-LDLT group 
and 8:11 in the LL-LDLT group, P < 0.0001). The 
patients’ diagnoses are shown in Table 1 and their 
perioperative details are shown in Table 2. The two 
groups of patients were significantly different in GW 
(P < 0.0001), GW/RSLV (P < 0.0001), and graft cold 
ischemic time (P = 0.007). Table 3 shows the patients’ 
survival outcomes and postoperative complications, 
as well as the reasons for graft losses and the causes 
of deaths. The only one significant difference between 
the groups was graft survival (P = 0.049), which can 
also be viewed in Figure 1. Figure 2 is a Kaplan-Meier 
plot for patient survival of the series (P = 0.476).
Donor details can be found in Table 4. Like the 
patients, the two groups of donors were similar in 
terms of age (median, 34 years in the RL-LDLT group 
and 32 years in the LL-LDLT group, P = 0.847) but had 
significantly different ratios of men to women (39:160 
in the RL-LDLT group and 16:3 in the LL-LDLT group, P 
< 0.001). When it comes to postoperative complication, 
the two groups of donors were comparable (16.6% in 
the RL-LDLT group and 5.3% in the LL-LDLT group, P = 
0.905). One donor death occurred and it was in the RL-
LDLT group (0.5% vs 0%, P = 1). The death was due to 
severe peptic ulcer disease resulting in aortoduodenal 
fistula.
On further analysis, patients with different GW/
RSLV (≤ 35% vs > 35%-40% vs > 40%- < 50%) 
were comparable in terms of graft survival and patient 
survival. No significant result was shown on multivariate 
analysis.
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that is inadequate to sustain metabolic demand in the 
recipient. The underlying reason for this is the presence 
of portal hypertension and graft size mismatch. This 
condition leads to a reduction in intrahepatic vascular 
bed with higher portal flow per gram of liver tissue, 
which leads to a rise in portal pressure and sinusoidal 
shear stress. Such stress may cause sinusoidal 
endothelial cell injury and provoke a sequence of 
hepatocellular damage and cell death[14,33,34], which 
is manifested by hepatocyte ballooning, steatosis, 
centrilobular necrosis and parenchymal cholestasis in 
the histology of the engrafted liver[35-37].
The current study found that SFS RL graft and SFS 
LL graft did not have much difference when patient 
survival is concerned - which echoes the results in 
the literature[38,39] - but the SFS RL grafts had better 
survival than the SFS LL grafts (P = 0.049). This study 
is a single-center retrospective study. At our center, RL-
LDLT has been the standard for years whereas LL-LDLT, 
despite the technical similarity, is a relatively unfamiliar 
procedure, which is also reflected in the small number 
of patients in the LL-LDLT group. Probably we were still 
at the learning-curve phase in LL-LDLT. Furthermore, 
this group of patients underwent transplant for liver 
failure. In an acute condition (such as acute liver 
failure or fulminant liver failure), the patient would be 
very sick with a high MELD score. In the past, patients 
with high MELD scores were denied LDLT because it 
would be unwise to put donors in risk for recipient 
outcomes that would be inferior. However, studies 
have shown that LDLT can provide patients who have 
high MELD scores with excellent graft function and 
patient survival[24,40,41]. The preference for RL graft is 
due to the shorter cold ischemic time and, in general, 
greater liver mass. Furthermore, almost all RL grafts 
we used contained the middle hepatic vein. The 
inclusion of the middle hepatic vein in a graft allows 
better venous drainage of the graft and hence ensure 
good liver function to meet the metabolic demand 
even if the patient is in critical condition[42]. Therefore, 
the use of LL graft needs justification, especially in the 
face of acute liver failure. Having said that, LL graft 
DISCUSSION
Liver transplant has been documented as a life-
saving treatment for liver failure and the result is 
remarkable[25]. However, the scarcity of liver grafts 
from deceased donors remains a major issue while 
the number of patients waiting for a liver transplant 
is rising[26,27]. The problem has led to not only the 
employment of LDLT but also the use of suboptimal 
liver grafts - grafts with mild steatosis and grafts 
from older donors, obese donors, and donors with a 
borderline small potential residual liver volume[28-31]. 
At our center, the use of RL for LDLT has been well 
established with satisfactory long-term graft survival 
and patient survival[32].
This study reviewed the outcomes of LDLT in 
patients who received a SFS graft. These patients were 
prone to SFS syndrome. SFS syndrome is defined by 
the presence of prolonged cholestasis, coagulopathy 
and ascites in the absence of ischemia within the first 
week of liver transplant caused by a partial liver graft 
Table 1  Patients’ demographic characteristics and diagnoses
RL-LDLT LL-LDLT P value
(n  = 199) (n  = 19)
Median age (yr) (range) 53 (17-72) 52 (17-67) 0.997
Male:Female 165:34 8:11 0.000
Diagnosis
   Liver cirrhosis
      Cryptogenic   3 1
      Hepatitis B virus infection 85 0
      Hepatitis C virus infection 15 5
      Alcohol   4 0
      Infection of hepatitis B and C viruses   2 0
      Alcohol + hepatitis C virus infection   3 0
      Alcohol + hepatitis B virus infection   1 0
   Chronic active hepatitis B   1 1
   Fulminant hepatic failure
      Cryptogenic   1 1
      Hepatitis B   2 0
      Autoimmune   1 0
      Drug-induced   3 1
   Biliary atresia   2 0
   Primary sclerosing cholangitis   0 1
   Primary biliary cirrhosis   2 1
   Graft failure   4 0
   Liver cirrhosis with acute 
   deterioration
      Cryptogenic   2 0
      Hepatitis B 30 3
      Alcohol   1 0
      Autoimmune   1 0
      Wilson's disease   2 0
   Chronic active hepatitis with acute 
   flare
      Hepatitis B 32 1
      Autoimmune   1 0
   Osler-Weber-Rendu syndrome   1 0
   Neuroendocrine syndrome   0 1
   Familial amyloid polyneuropathy   0 1
   Caroli disease   0 1
   Recurrent pyogenic cholangitis   0 1
   Hepatocellular carcinoma 83 (41.7%) 5 (26.3%) 0.191
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can still provide reasonable recipient survival. Most 
importantly, a LL living donor risks much less than a 
RL living donor. Further comparison between LL and 
RL grafts can be made when more LL-LDLTs have been 
performed for different types of patients with different 
conditions.
In this study, most of the patients in the LL-LDLT 
group were women. In general, women have a smaller 
body size. So, although the grafts were lighter and had 
a smaller GW/RSLV, they fitted well in the patients, 
who were mostly women. Women with a lower body 
mass index and a low-to-medium MELD score have 
been found to be disadvantaged in the “MELD score 
era” because of the heavy influence of creatinine level 
on MELD score; they tend to have a lower priority 
on the liver transplant waitlist and a higher waitlist 
mortality[43-45]. Balancing donor risks and recipient 
outcomes, even if there is graft size mismatch, the use 
of LL graft for LDLT can potentially expand the donor 
pool to shorten the waiting time and, at the same 
time, lower the donor risk.
The mortality risk for donors is 0.1% for LL-LDLT 
and 0.5% for RL-LDLT[8]. The figures are small and 
at first sight there seems to be not much difference. 
However, in the long run if a large number of living 
Table 2  Patients’ perioperative details
RL-LDLT LL-LDLT P value
(n  = 199) (n  = 19)
Waiting time (d) 11 (1-1354) 16 (1-381) 0.190
Preoperative MELD score 20 (6-50) 14 (6-40) 0.184
GW (g) 530 (320-715) 410 (310-585) 0.000
GW/RSLV (%) 42.8 (28.4-46.998) 36.3 (27.3-46.96) 0.000
GW/RBW (%) 0.77 (0.46-1.03) 0.72 (0.49-1.04) 0.236
Graft cold ischemic time (min) 105 (53-243) 85 (69-134) 0.007
Recipient warm ischemic time (min) 51 (25-89) 45 (27-63) 0.088
Splenic artery ligation 0 0 -
Portosystemic shunt 0 0 -
Ligation of shunt 2 (1.0%) 0 1.000
Blood transfusion (units) 4 (0-39) 2 (0-14) 0.099
Fresh frozen plasma transfusion (units) 9 (0-38) 6 (0-23) 0.145
Platelet transfusion (units) 6 (0-32) 3 (0-22) 0.341
Operation time (min) 685 (400-1203) 670 (485-1273) 0.738
Intensive care unit stay (d) 4 (1-124) 6 (2-16) 0.055
Hospital stay (d) 17 (2-128) 23 (10-68) 0.072
Follow-up period (d) 86.9 (0.07-162.9) 133.7 (0.53-159.2) 0.054
Data are presented as median (range). MELD: Model for End-stage Liver Disease; GW: Graft weight; RSLV: Recipient standard liver volume; RBW: 
Recipient body weight; LDLT: Living-donor liver transplantation; LL: Left-lobe; RL: Right-lobe.
Table 3  Survival outcomes and postoperative complications 
in recipients  n  (%)
RL-LDLT LL-LDLT P value
(n  = 199) (n  = 19)
In-hospital death 4 (2) 1 (5.3) 0.918
Graft loss 33 (16.6) 5 (26.3) 0.452
Patient status - Alive:Dead 169:30 15:4 0.722
Graft survival 0.049
   1-yr 98.50% 89.50%
   3-yr 95.80% 89.50%
   5-yr 95.20% 89.50%
Patient survival 0.476
   1-yr 95.90% 89.50%
   3-yr 90.80% 89.50%
   5-yr 86.80% 89.50%
Postoperative complication1 0.105
   No complication 92 (46.2) 7 (36.8)
   Grade 1 42 (21.1) 3 (15.8)
   Grade 2 21 (10.6) 0
   Grade 3a 19 (9.5) 5 (26.3)
   Grade 3b 14 (7.0) 3 (15.8)
   Grade 4a 7 (3.5) 0
   Grade 4b 2 (1.0) 0
   Grade 5 2 (1.0) 1 (5.3)
Reason for graft loss
   Patient death 28 3
   Hepatic artery thrombosis   1 0
   Portal vein thrombosis   1 0
   PV/IVC thrombosis   1 0
   Recurrent Wilson's disease   1 0
   Biliary complication   0 1
   Reactivation of hepatitis C   0 1
   Rejection   1 0
Cause of death
   Acute myocardial infarction   2 0
   Chronic rejection   1 0
   Unknown   2 0
   Invasive aspergillosis   1 0
   Malignant cachexia 16 0
   Sepsis/multiorgan failure   3 2
   Subarachnoid hemorrhage   1 0
   Graft failure from PV/IVC 
   thrombosis
  1 0
   Lymphoproliferative disease   1 0
   Pulmonary hypertension   1 0
   Respiratory failure   1 0
   Chronic heart failure   0 1
   Reactivation of hepatitis C   0 1
1Clavien grading. PV: Portal vein; IVC: Inferior vena cava; LDLT: Living-
donor liver transplantation; LL: Left-lobe; RL: Right-lobe.
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donors are donating their RLs, the mortality of RL 
living donors will be significant. In this study, the donor 
mortality rates - 0.5% in RL-LDLT and 0% in LL-LDLT - 
were similar to the rates recorded in the literature.
The first successful LL-LDLT was reported in 
1994[46]. Generally, a LL graft is 30%-40% of the SLV 
in adults[7]; as such, SFS syndrome tends to develop. 
SFS syndrome often results in poor graft survival and 
patient survival[9,14-16]. However, it has been shown 
that LL-LDLT can achieve excellent graft survival and 
patient survival[4] and the results of LL-LDLT can be 
comparable to those of RL-LDLT[17-21]. The primary 
goal of LDLT is to minimize donor risks (morbidity and 
mortality) while maximizing recipient benefits.
Using LL graft instead of RL graft has the 
advantage of lower donor morbidity[47] and mortality[8], 
but sometimes a LL graft would not suffice. If the 
prognosis for a patient is poorer because of a high 
MELD score or an old donor age, using the larger 
RL would improve the transplant outcome[19]. In the 
current study, all the grafts were small for size, and 
LL-LDLT and RL-LDLT had little difference when long-
term patient survival is concerned. In view of this, 
maybe we can opt for the LL more often. For patients 
with a low MELD score and relatively stable condition, 
if a deceased-donor graft is unavailable, the use of LL 
graft can be advocated after balancing donor risks and 
potential recipient outcomes.
At our center, if SFS syndrome is expected, flow 
modulation will be performed. In the operation, portal 
flow and portal pressure are measured. Additional 
portal inflow modulations, such as splenic artery 
ligation[23] and portocaval shunt[48] may be employed[49]. 
In the current study, although all grafts were small for 
size, not many patients needed flow modulation. Some 
patients even required ligation of the spontaneous 
portosystemic shunt due to inadequate portal flow. All 
patients had good outcomes.
We wanted to find out the risk for complication 
and mortality in using SFS LL graft. Unfortunately, due 
to the small number of cases that used SFS LL graft, 
it was difficult to run a statistic on it. A multivariate 
analysis on the relevant data was performed but the 
result was negative; it was a nonsignificant finding.
The findings of this study may not be universally 
applicable. Our center is experienced in LDLT, especially 
RL-LDLT, which might have contributed to the favorable 
outcomes in the study[32]. Moreover, there were only 
19 patients in the LL-LDLT group. The study has a 
relatively high risk of type-2 error. Furthermore, this is 
a retrospective cohort study with inevitable selection 
bias. Although every LDLT center has its LDLT protocol, 
every LDLT should be individualized, and the selection 
criteria adopted by a center cannot be universally 
applied.
The use of SFS graft in LDLT requires careful tailor-
made surgical planning and meticulous operation. LL-
LDLT can be a good alternative to RL-LDLT with similar 
recipient outcomes but a lower donor risk. Further 
research into different patient conditions is needed in 
order to validate the use of LL graft.
COMMENTS
Background
The use of the right lobe graft in living donor liver transplantation has been well 
established. However the use of the left lobe graft remained cautious, as a lot 
of patients suffered from complication or mortality due to the small for size graft. 
This study reviewed the results of the use of small for size grafts (left lobe or 
right lobe) and analyzed the outcomes of transplantation using left lobe small 
for size graft.
Research frontiers
Donor safety is of paramount importance in living donor liver transplantation. 
In the past, the mortality rate for right lobe graft donation was around 0.5%, 
whereas the mortality rate for left lobe graft donation was around 0.1%. The 
result of using right lobe small for size graft has been well established. However 
comparison between right lobe small for size graft and left lobe small for size 
graft is scarce.
Innovations and breakthroughs
This paper focused on the graft outcome and patient outcome of using small 
for size graft. Although the use of the right lobe and the use of the left lobe 
achieved similar patient survival, we should analyze the results cautiously, as 
most of the time recipients using a left lobe graft were relatively less risky.
Applications
This study has delivered an important message that allows further enlargement 
of the donor pool. Left lobe small for size graft can achieve results similar to 
right lobe small for size graft while reducing donor risk. Further studies can be 
conducted to find out which subgroup of patients would benefit from left lobe 
graft the most and to decide the safety limit of using left lobe small for size 
grafts.
Terminology
Right lobe graft: A graft that is the right liver lobe, usually containing the middle 
hepatic vein; Left lobe graft: A graft that is the left liver lobe; Small for size 
graft: A graft with a ratio of graft weight to recipient standard liver volume of < 
40%-50%, or with a ratio of graft to recipient weight of 0.8%-1.0%; Small for 
size syndrome: Constellation of cholestasis, coagulopathy and ascites. It can 
progress to gastrointestinal bleeding and renal failure.
Table 4  Donor details
RL-LDLT LL-LDLT P value
(n  = 199) (n  = 19)
Male:Female 39:160 16:3 0.000
Median age (yr) (range) 34 (18-58) 32 (18-55) 0.847
Death  1 (0.5%)   0 1.000
Postoperative complication1 0.905
   No complication 166 18
   Grade 1   14   1
   Grade 2     8   0
   Grade 3a     4   0
   Grade 3b     5   0
   Grade 4a     1   0
   Grade 4b     0   0
   Grade 5     1   0
1Clavien grading. LDLT: Living-donor liver transplantation; LL: Left-lobe; 
RL: Right-lobe.
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